CTI Clinical Trial and Consulting Expands Use of Oracle Applications
CTI upgrades to new releases of remote data entry and adverse event reporting products from Oracle
CTI Clinical Trial and Consulting Supports Growing Business with Expanded Oracle Clinical Footprint
Use of Oracle® Remote Data Capture Enables More Agile Reporting to Regulatory Organizations
Redwood Shores, CA – November 3, 2008
News Facts
· CTI<http://www.ctifacts.com/> Clinical Trial and Consulting Services (CTI)<http://www.ctifacts.com/> is upgrading and expanding its use of Oracle applications for clinical development to support the company’s continued growth in the U.S. and global markets.
· CTI, a specialty drug and market development company based in Cincinnati, Ohio, has recently upgraded to the newest releases of Oracle® Clinical<http://www.oracle.com/industries/life_sciences/oracle-clinical-data-sheet.pdf> and Oracle Adverse Event Reporting System<http://www.oracle.com/industries/life_sciences/aers45_datasheet.pdf>.
· The company is also upgrading to Oracle Remote Data Capture 4.5.3<http://www.oracle.com/industries/life_sciences/rdc-onsite-datasheet.pdf>, Oracle’s electronic data capture (EDC) solution, to leverage new functionality designed to meet the needs of trial sponsors and investigative site personnel, including the product’s zero-client footprint that enables improved global access.
· The growing company, which serves more than 50 biotech and pharmaceutical organizations globally is expanding its Oracle footprint with the deployment of Oracle Clinical Trial Management System<http://www.oracle.com/applications/crm/siebel/resources/siebel-lifescience-clinical-trial-management-system-data-sheet.pdf>, moving from a system developed in house to a best-of-breed solution that provides greater scalability and flexibility in managing all aspects of clinical study planning, preparation, performance and reporting.
· The company focuses on developing therapies targeting very ill patients. The clinical trial process for such drugs often requires more frequent, extensive and rapid reporting to a trial’s Data Safety Monitoring Board (DSMB), an independent body responsible for assessing a study and its risk.
· With Oracle Clinical and Oracle Remote Data Capture, CTI can quickly deliver data to a DSMB or regulatory agencies, such as the U.S. Food and Drug Administration (FDA), without the need to key in information from paper case report forms (CRFs) – a process that is time consuming and presents opportunities for data entry error.
· CTI conducts approximately 60 percent of its trials using EDC technology.
· The 10-year old company invested in industry-leading Oracle Clinical applications at its inception to help credential it in the market.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
